已發(fā)表的部分文獻(xiàn): 標(biāo)題:Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.作者:Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE, Huang Y;雜志名稱:Breast Cancer Res Treat 標(biāo)題:Epigenetic assays for chemical biology and drug discovery.作者:Gul S;雜志名稱:Clin Epigenetics 標(biāo)題:4,5-Dimethoxycanthin-6-one is a novel LSD1 inhibitor that inhibits proliferation of glioblastoma cells and induces apoptosis and pyroptosis.作者:Li W, Huang BS, Xiong YY, Yang LJ, Wu LX;雜志名稱:Cancer Cell Int 標(biāo)題:TNF?± Induces DNA and Histone Hypomethylation and Pulmonary Artery Smooth Muscle Cell Proliferation Partly via Excessive Superoxide Formation.作者:Crosswhite P, Sun Z;雜志名稱:Antioxidants (Basel) Epigentek 公司是全球領(lǐng)先的表觀遺傳學(xué)相關(guān)研究的技術(shù)創(chuàng)新者和產(chǎn)品開(kāi)發(fā)供應(yīng)商。開(kāi)發(fā)了超過(guò)700多個(gè)專利產(chǎn)品,為表觀遺傳學(xué)方面的研究和新藥研發(fā)提供全面系統(tǒng)的解決方案,涵蓋樣品制備、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、組蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等領(lǐng)域,提供小分子抑制劑、蛋白質(zhì)、抗體、以及分析試劑盒產(chǎn)品。